I've been sitting on the sidelines lately (with popcorn).
IMO these SP levels are fair. All too often people get hyped with pharma prospect and potential.
They are essentially an R&D company. Zero (or next to zero) revenue. Investors are hopeful that one of IHLs many product pipelines might materialise into therapeutic benefit for many, many patients. There's also the prospect of big pharma acquiring one or all of their portfolio.
But anyone's dismay at the SP at the moment needs to accept that it's part of the journey, and the run up to $0.70 was unrealistic and H Y P E.
I agree with most that the recent CR was a slap in the face (not for me personally, but for those that jumped in at the last CR). Though I'm inclined to trust management, despite old mate jumping ship (amber flag for me).
The road to commercialisation is hefty.
Those with a weak stomach should exit the ride.
GLTAH.
P.S the zealots on either side need to relax
IHL Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
